Johnson & Johnson: PharmaVitae Profile

Table of Contents

ABOUT THIS PROFILE

• PharmaVitae Explorer database
• Chapter structure
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors

• Data sourcing
  • Analyst consensus

EXECUTIVE SUMMARY

• Key findings
• Prescription pharmaceutical sales and growth rate performance, 2002 - 14
• Financial performance, 2002 - 14
• Johnson & Johnson: PharmaVitae forecasts at a glance
• Strategic insight
  • Managing the boom & bust of ‘blockbuster' drugs
  • Despite challenges, J&J' s outlook appears robust
  • Wide range of strategic options to seek growth

• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

QUARTERLY NEWS UPDATE

• Key findings
• Product developments
• Deals and alliances
  • Technology deals

• M&A activity
  • Company announcements
  • Future product milestones

COMPANY INTRODUCTION

• Key findings
• Background
• Key corporate developments
• M&A history
  • M&A strategy

• Current corporate structure

COMPANY SALES

• Key findings
• Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
• Product analysis
  • Product analysis, 2002 - 08
  • Product analysis, 2008 - 14

• Therapy area analysis
• Geographic analysis
• Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008 - 14
  • Core analysis, 2008 - 14
  • Expiry analysis, 2008 - 14
  • Generics analysis, 2008 - 14

• Molecule type analysis
• Externalization analysis

COMPANY FINANCIALS

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002 - 08
• Operating costs and profit analysis
  • Operating costs and profit analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2008 - 14
  • Operating costs and profit analysis, 2008 - 14

KEY PRODUCTS AND COMPETITORS

• Key findings
• Overview
• Central nervous system
  • Risperdal franchise
  • Invega franchise
  • Topamax

• Immunology & inflammation
  • Remicade
  • Simponi (golimumab)
  • Stelara (ustekinumab)

• Oncology
  • Velcade
  • Procrit

• Cardiovascular
  • Xarelto

• Infectious diseases
  • Prezista

APPENDIX

• R&D pipeline
• Remicade sales reconciliation
• References
• Abbreviations
• Exchange rates

TABLES

• Table: Johnson & Johnson - PharmaVitae forecasts at a glance
• Table: Johnson & Johnson key product developments, Q1 - Q2 2009
• Table: Johnson & Johnson product deals and alliances, Q1 - Q2 2009
• Table: Johnson & Johnson technology deals and alliances, Q1 - Q2 2009
• Table: Johnson & Johnson M&A activity, Q1 - Q2 2009
• Table: Johnson & Johnson company announcements, Q1 - Q2 2009
• Table: Johnson & Johnson future product milestones, 2009 - 10
• Table: Johnson & Johnson product portfolio overview ($m), 2002 - 08
• Table: Johnson & Johnson product portfolio overview ($m), 2008 - 14
• Table: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2008 - 14
• Table: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2008 - 14
• Table: Johnson & Johnson launch portfolio overview ($m), 2008 - 14
• Table: Johnson & Johnson core portfolio overview ($m), 2008 - 14
• Table: Johnson & Johnson expiry portfolio overview ($m), 2008 - 14
• Table: Johnson & Johnson generics portfolio overview ($m), 2008 - 14
• Table: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2008 - 14
• Table: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2008 - 14
• Table: Total Johnson & Johnson sales by business unit ($m), 2002 - 08
• Table: Johnson & Johnson operating revenue/cost analysis ($m), 2002 - 08
• Table: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2002 - 08
• Table: Johnson & Johnson operating cost ratio analysis (% of total revenues), 2008 - 14
• Table: Johnson & Johnson operating revenue/cost analysis ($m), 2008 - 14
• Table: Key products overview
• Table: Risperdal: overview
• Table: Risperdal franchise: sales forecast ($m), 2008 - 14
• Table: Invega: overview
• Table: Invega franchise: sales forecast ($m), 2008 - 14
• Table: Topamax: overview
• Table: Topamax: sales forecast ($m), 2008 - 14
• Table: Remicade: overview
• Table: Remicade: sales forecast ($m), 2008 - 14
• Table: Simponi: overview
• Table: Simponi: sales forecast ($m), 2008 - 14
• Table: Stelara: overview
• Table: Stelara: sales forecast ($m), 2008 - 14
• Table: Velcade: overview
• Table: Velcade: sales forecast ($m), 2008 - 14
• Table: Procrit: overview
• Table: Procrit: sales forecast ($m), 2008 - 14
• Table: Xarelto: overview
• Table: Xarelto: sales forecast ($m), 2008 - 14
• Table: Prezista: overview
• Table: Prezista: sales forecast ($m), 2008 - 14
• Table: Johnson & Johnson' s R&D pipeline (Phase I - registration)
• Table: Total Remicade sales forecast ($m), 2008 - 14
• Table: Exchange rates, 2009

FIGURES

• Figure: The PharmaVitae Explorer
• Figure: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Johnson & Johnson' s financial performance ($m), 2002 - 14
• Figure: Lifecycle management strategies boost key J&J franchises, 2002 - 14 ($m)
• Figure: Johnson & Johnson prescription pharmaceutical sales by stage, 2002 - 14 ($m)
• Figure: J&J' s strategic options for growth
• Figure: Johnson & Johnson SWOT analysis
• Figure: Recent & major M&A/ divestment activity, J&J
• Figure: Current corporate structure
• Figure: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Key product sales ($m), 2002 - 14
• Figure: Johnson & Johnson key sales growth drivers and resistors ($m), 2002 - 08
• Figure: Johnson & Johnson key sales growth drivers and resistors ($m), 2008 - 14
• Figure: Johnson & Johnson prescription pharmaceutical sales by therapy area ($m), 2002 - 14
• Figure: Johnson & Johnson prescription pharmaceutical sales by geographic region ($m), 2002 - 14
• Figure: Johnson & Johnson launch/core/expiry configuration ($m), 2008 - 14
• Figure: Johnson & Johnson prescription pharmaceutical sales by molecule type ($m), 2002 - 14
• Figure: Johnson & Johnson prescription pharmaceutical sales by source ($m), 2002 - 14
• Figure: Johnson & Johnson operating revenue/cost analysis ($m), 2002 - 14